PTC Therapeutics Inc., of South Plainfield, N.J., reported revenues of $56.1 million for the first quarter, with net product revenues of Duchenne muscular dystrophy drugs Translarna (ataluren) and Emflaza (deflazacort) totaling $36.8 million and $19.2 million, respectively. First-quarter net loss was $19.3 million.